Ten years of innovation, collaboration and a shared commitment to improving patient care has shaped Zai Lab into a fully integrated and innovative global biopharmaceutical company. Since its founding in 2014, Zai has focused on developing and commercializing innovative therapies that deliver meaningful outcomes to patients around the world.
We have always been mindful that there are no borders when it comes to innovation and patient needs. Over the past 10 years Zai Lab has rapidly built up a pipeline of potential first-in-class and/or best-in-class late-stage therapies, successfully developing and commercializing five therapies in China. Simultaneously, Zai has been actively invested in internal R&D initiatives, with several early-stage programs underway.
Over the next 10 years we will leverage our strengths and proven track record to continue to innovate and meet our commitment to patients. Anchored by our dedication to scientific excellence and uncompromising quality, our goal is to reach 1-million patients by 2030. We are committed to powering the future of global health.
Message from the Founder and CEO
“After a decade of growth and innovation Zai Lab stands on a solid foundation, ready to embark on its next chapter. We will continue to embrace our spirit of scientific entrepreneurship, being resilient in the face of challenges and continuing to look for new and better ways to meet patient needs. By focusing on innovative and differentiated therapies, we will continue to fill critical gaps in the therapeutic landscape to make a positive impact on patients’ lives.”
Samantha Du, Ph.D.
Founder, Chairperson and Chief Executive Officer
